Compass Therapeutics Inc.

NASDAQ CMPX

Data sourced from

and

Download Data

Compass Therapeutics Inc. Current Liabilities to Total Liabilities Ratio 3 year CAGR for the quarter ending March 31, 2024: 8.98%

Compass Therapeutics Inc. Current Liabilities to Total Liabilities Ratio 3 year CAGR is 8.98% for the quarter ending March 31, 2024, a 316.15% change year over year. The current liabilities to total liabilities ratio measures the proportion of a company's current liabilities in relation to its total liabilities. It is calculated by dividing current liabilities by total liabilities. This ratio provides insights into the percentage of a company's total liabilities that are classified as current liabilities. It helps evaluate the company's overall liability structure and the importance of short-term obligations in relation to total liabilities. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Compass Therapeutics Inc. Current Liabilities to Total Liabilities Ratio for the quarter ending March 31, 2023 was 0.88, a 13.89% change year over year.
Compass Therapeutics Inc. Current Liabilities to Total Liabilities Ratio for the quarter ending March 31, 2022 was 0.77, a 4.93% change year over year.
Compass Therapeutics Inc. Current Liabilities to Total Liabilities Ratio for the quarter ending March 31, 2021 was 0.74, a -26.33% change year over year.
Compass Therapeutics Inc. Current Liabilities to Total Liabilities Ratio for the quarter ending March 31, 2020 was 1.00, a 0.00% change year over year.

NASDAQ: CMPX

Compass Therapeutics Inc.

CEO	Dr. Thomas J. Schuetz M.D., Ph.D.
IPO Date	April 5, 2021
Location	United States
Headquarters	80 Guest Street, Boston, MA, United States, 02135
Employees	32
Sector	Healthcare
Industry	Biotechnology

Description

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Key trends